AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01088022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Palonosetron, Dexamethasone
Description: Aprepitant 125-mg placebo capsule 80-mg placebo capsule 80-mg placebo capsule Palonosetron 0.25 mg i.v. Dexamethasone 8 mg i.v. 8 mg os 8 mg os
Study NCT01824186 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LC
Description: Underwent conventional 4-port laparoscopic cholecystectomy
Study NCT00898391 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00898391 — intervention group
Intervention type: GENETIC
Intervention: polymerase chain reaction
Description: Correlative studies
Study NCT00898391 — intervention group
Intervention type: GENETIC
Intervention: polyacrylamide gel electrophoresis
Description: Correlative studies
Study NCT00898391 — intervention group
Intervention type: GENETIC
Intervention: DNA analysis
Description: Correlative studies
Study NCT02238834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP-025
Description: Subjects will receive single doses of 200 to up to 800 mg of FP-025 (API-in-capsule) in a dose escalation format (cohorts 1-3). Subjects will receive single doses of 50 to up to 450 mg of FP-025 (ASD-in-capsule) in a dose escalation format (cohorts 4-8).
Study NCT02238834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive single doses of FP-025 matching placebo (capsule) in a dose escalation format.
Study NCT02238834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP-025
Description: Subjects will receive doses of FP-025 (capsule) twice daily for 5 days.
Study NCT02238834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive FP-025 matching placebo (capsule) twice daily for 5 days
Study NCT02149017 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SNUBH-NM-333(18F)
Description: 5-10 mCi
Study NCT00389675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darusentan
Description: Darusentan capsules at a dose of 50, 100, or 300 mg administered orally once daily
Study NCT00389675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guanfacine
Description: Guanfacine 1 mg capsules administered orally once daily
Study NCT04322825 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS incorporated into the Mollii suit
Description: trans cutaneous electric stimulation,
Study NCT03921177 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplement
Description: Preconception to 12-weeks gestation: daily (coded) multiple micronutrient supplement containing 15-nutrients (vitamins and minerals) providing an approximate recommended dietary allowance for pregnant women, approximating the UNICEF UNIMAP formulation (UN micronutrient preparation).
Study NCT03921177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Preconception to 12-weeks gestation: identical tablet
Study NCT04190277 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open-loop condition
Description: Patient's standard insulin pump setting combined with continuous glucose monitoring sensor
Study NCT04190277 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open-loop condition
Description: Patient's standard insulin pump setting combined with continuous glucose monitoring sensor
Study NCT04190277 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop condition
Description: Closed-loop algorithm system paired with continuous glucose monitoring sensor
Study NCT04190277 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop condition
Description: Closed-loop algorithm system paired with continuous glucose monitoring sensor
Study NCT04316364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1316、Paclitaxel (Albumin Bound)、Carboplatin
Description: Drug: SHR-1316, an engineered anti-PD-L1 antibody will be administered as intravenous (IV) infusion on Day 1 of each 21-day cycle Drug: Paclitaxel (Albumin Bound) will be administered intravenously on Day 1,8,15 of each 21-day cycle Drug: Carboplatin will be administered intravenously on Day 1 of each 21-day cycle
Study NCT04316364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1316、Chemotherapeutic
Description: Drug: SHR-1316, an engineered anti-PD-L1 antibody will be administered as intravenous (IV) infusion on Day 1 of each 21-day cycle Drug: Chemotherapeutic drugs will be administered on Day 1 of each 21day cycle, if applicable, they will also be administered on Day 8 and/or Day 15 according to the drug package insert
Study NCT04316364 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo、Chemotherapeutic
Description: Drug: Placebo, will be administered as intravenous (IV) infusion on Day 1 of each 21-day cycle Drug: Chemotherapeutic drugs will be administered on Day 1 of each 21day cycle, if applicable, they will also be administered on Day 8 and/or Day 15 according to the drug package insert
Study NCT03574428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GNbAC1
Description: Monoclonal Antibody infused i.v.
Study NCT03574428 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GNbAC1 Placebo
Description: Equivalent to GNbAC1 Buffer
Study NCT04916379 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Momordica charantia
Description: Momordica Charantia: 2000 mg per day for 12 weeks
Study NCT04916379 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 2000 mg per day for 12 weeks
Study NCT04412447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation
Description: Electrical stimulation of motor-nerves innervating the musculature of the lower limb.
Study NCT03030339 — intervention group
Intervention type: OTHER
Intervention: High VA intake, recent VAS
Description: Children who are exposed to multiple VA programs, have received a high-dose VA supplement (VAS; 200,000 IU) in the past month, and are identified as being likely to have chronic excessive dietary VA intake.
Study NCT03030339 — intervention group
Intervention type: OTHER
Intervention: High VA intake
Description: Children who are exposed to multiple VA programs, have received a high-dose VA supplement (200,000 IU) in the past 3-6 months, and are identified as being likely to have chronic excessive dietary VA intake.
Study NCT03030339 — intervention group
Intervention type: OTHER
Intervention: Low/adequate VA intake
Description: Children who are not exposed to multiple VA programs, have received a high-dose VA supplement in the past 3-6 months, and are identified as being likely to have chronic low to adequate dietary VA intake.
Study NCT02161107 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grass-SPIRE
Description: Intradermal injection
Study NCT02161107 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal injection
Study NCT01722435 — intervention group
Intervention type: DRUG
Intervention: Opiate Substitution Treatment
Study NCT03507712 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Symmetrical IO weakening
Description: Bilateral IO Myectomy / Bilateral equal graded IO Recession
Study NCT03507712 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Asymmetrical IO weakening
Description: IO Myectomy in one eye - IO Recession in the fellow eye / Bilateral IO Recession (different amounts) in each eye
Study NCT03524807 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrophysiologic therapy
Description: Pelvic floor electrophysiological therapy is used after common gynecologic surgery to record anal exhaust time and micturition time after surgery and endometrium recovery of intrauterine adhesions.For intrauterine adhesions patients, Drug: Aspirin(low dose of Aspirin after operation)Device: intrauterine balloon (insert intrauterine balloon after operation)
Study NCT03704961 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music and audiobook listening
Study NCT03458533 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric surgery
Study NCT03458533 — intervention group
Intervention type: BEHAVIORAL
Intervention: Diet and lifestyle changes
Study NCT02245841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H.P. Acthar Gel
Description: 80 U (1 mL) of H.P. Acthar gel via subcutaneous injection twice weekly for 24 weeks
Study NCT00481195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Armodafinil
Description: Patients were randomly assigned to begin oral treatment with armodafinil, which was titrated to 150 mg/day (3 tablets). Armodafinil was titrated up to the target dosage of 150 mg/day (daily dose was administered each morning). Patients began taking blinded armodafinil at a dose of 50 mg/day (1 tablet) on the day following the baseline visit. Doses were increased by 50 mg/day (1 tablet) to a dose of 100 mg/day on Day 2 and 3, and then again by 50 mg /day on day 4 for a target dose of 150 mg/day. Following titration, patients continued taking 150 mg/day of armodafinil for the duration of the study. If a patient was unable to tolerate (recurrent or persistent adverse events) the study drug, 1 reduction in dosage (ie, minimum dosage 100 mg/day \[2 tablets\]) was allowed. The dosage could not be increased after it was decreased.
Study NCT00481195 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients were randomly assigned to begin oral treatment with placebo, which was titrated to 3 tablets. Placebo tablets matching the 50 mg armodafinil tablet were used in a manner identical to that of the armodafinil tablets. Study drug was titrated up to the target dosage of 3 tablets / day (daily dose was administered each morning). Patients began taking blinded study drug at a dose of 1 tablet daily on the day following the baseline visit. Doses were increased by 1 tablet to a dose of 2 tablets/day on Day 2 and 3, and then again by 1 tablet /day on day 4 for a target dose of 3 tablets/day. Following titration, patients continued taking 3 tablets/day of study drug for the duration of the study. If a patient was unable to tolerate (recurrent or persistent adverse events) the study drug, 1 reduction in dosage (ie, minimum dosage 2 tablets/day) was allowed. The dosage could not be increased after it was decreased.
Study NCT01960946 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Modified Citrus Pectin (MCP) vs placebo
Description: 5 grams by mouth three times a day
Study NCT01960946 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Modified Citrus Pectin (MCP) vs placebo
Description: 5 grams by mouth three times a day
Study NCT02290106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pitavastatin
Study NCT02290106 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Study NCT02876900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Asenapine maleate transdermal patch
Description: The study will evaluate low dose Asenapine maleate transdermal patch
Study NCT02876900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Asenapine maleate transdermal patch
Description: The study will evaluate high dose Asenapine maleate transdermal patch
Study NCT02876900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The study will evaluate placebo transdermal patch.
Study NCT02876900 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study will evaluate placebo transdermal patch.
Study NCT03961542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing
Description: Eligible patients are randomized to receive either routine care (control group) or routine care in addition to a chewing gum intervention for five days (beginning with the second study day, i.e. the day after baseline examination): sugar-free, fruit or mint flavoured gum chewed three times daily for 20 minutes before each meal. Routine care includes standard dietary and lifestyle advice for 30 minutes following our local recommendations as well as an advice on capillary blood glucose measurement (fasting as well as 1h after starting each meal). Capillary blood glucose profiles are reevaluated seven days after starting the blood glucose monitoring. Study visits will be scheduled at screening (visit 1, where eligible patients were randomized) as well as seven days later (visit 2).
Study NCT00370253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: 1mg/4 h per day
Study NCT00370253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Noradrenalin
Description: 0,1 mcg/kg/min
Study NCT02141997 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: adalimumab administered as subcutaneous injection every other week (EOW)
Study NCT04288661 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No drain placement
Description: The need of perianastomotic drain placement after Roux-en-Y reconstruction in total gastrectomy operations is investigated. As intervention, no drain placement is considered
Study NCT02243449 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Once daily screening
Description: In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met. The initial SBT will be 30-120 minutes in duration and may be conducted with any one of the following techniques: T-piece, continuous positive airway pressure (CPAP) less than or equal to 5 cm H2O or PS less than or equal to 8 cm H2O with PEEP less than or equal to 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and use of different humidification strategies. Each centre will be asked to choose one technique to be used for patients enrolled at their centre.
Study NCT02243449 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: At least twice daily screening
Description: In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met. The initial SBT will be conducted in the same manner as in the once daily screening arm. The subsequent SBTs will be 30 -120 minutes in duration and may be conducted with any one of the following techniques: T-piece, CPAP \< to 5 cm H2 O or PS \< 8 cm H2 O with PEEP \< 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and with the use of different humidification strategies. Each centre will be asked to choose one technique for all patients enrolled at their centre.
Study NCT01580436 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tricuspid Valve Annuloplasty
Description: Concomitant Tricuspid Valve Annuloplasty in patients undergoing mitral valve surgery
Study NCT04084275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutrition education
Description: In this training, the amount of nutrients that breastfeeding women should take daily was explained.
Study NCT04084275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fatigue education
Description: In this training, suggestions were made to prevent the negative effects of fatigue
Study NCT04084275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sleep education
Description: In this training, suggestions were offered the puerperants for better sleep. Strategies to improve sleep quality were explained.
Study NCT04084275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pilates exercises education
Description: In this study, pilates exercises exclusively for postpartum women were selected from two reference books, Fitness Professional's Handbook and Guide Women's and Fitness Health, which include 13 movements: Bridging, Hundred, Roll Up, One Leg Circle (both ways), Rocker with close legs,Single Straight Leg Stretch, Double Leg Stretch, Spine Stretch Forward, Single Leg Kick, Side Kick up and down, Side Kick circles, Rest position (stretch and relaxation) and Curling. The trainings were provided by the investigator during home visits to the puerpera in the intervention group and the pilates exercises by the investigator who was also a pilates trainer. An appropriate setting was prepared at the homes of puerpera so that they could do the pilates exercises easily.
Study NCT01730768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQW051
Study NCT01730768 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02290990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imaginative Distention technique
Description: ID is an Imaginative relaxation technique which combines physical and mental relaxation. ID technique reaches physical relaxation through planned alternated movements taken from Jacobson PMRT which consist of specific muscle contractions and subsequent relaxations, with a precise temporal scanning. Psychological relaxation is achieved thanks to mental imagery (motor imagery, body scan, imagination).
Study NCT02290990 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Imaginative Distention technique
Description: ID is an Imaginative relaxation technique which combines physical and mental relaxation. ID technique reaches physical relaxation through planned alternated movements taken from Jacobson PMRT which consist of specific muscle contractions and subsequent relaxations, with a precise temporal scanning. Psychological relaxation is achieved thanks to mental imagery (motor imagery, body scan, imagination).
Study NCT01135368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole capsules
Study NCT00824746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib retreatment
Description: phase II trial of Gefitinib retreatment for the advanced or metastatic (IIIb and IV) NSCLC patients who previously responded to gefitinib And progressive disease should be observed with at least one prior regimen following previous EGFR-TKI failure.
Study NCT04126759 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P0.3
Description: Subjects will perform daily measurements on the IMD (Prototype 0.3) for 35 days.
Study NCT00809549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 10 ug/kg sc once daily x 4 days. Repeated once, 6 weeks later.
Study NCT00809549 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Filgrastim
Description: 10 ug/kg sc once daily x 4 days. Repeated once, 6 weeks later.
Study NCT04449016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: Repeated, brief, and intense exercise bouts separated by active recovery
Study NCT04268173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-Based, Client-Centered Prevention Home
Description: Prevention Navigators at Vivent Helath offices will engage participants in risk assessments, goal planning, and treatment referrals based on their needs and desires.
Study NCT03404856 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ORL-1G - D-galactose
Description: Oral ORL-1G - D-galactose
Study NCT01304407 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Calcium stable isotope
Description: Subjects consume breakfast and 180 ml of calcium-fortified orange juice to which 20 mg of 46Ca stable isotope was added. Immediately after breakfast, subjects receive 5 mg of 42Ca intravenously.
Study NCT04353700 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga group
Description: During the in-home yoga intervention, participants performed 30 to 50 minutes of yoga postures three to five times a week for 12 weeks, including 5 minutes of warm-up exercise, 15 to 30 minutes of dynamic flow yoga postures, 10 minutes of weight barring standing postures, and 5 minutes of cool-down. These in-home sessions were a repeat of what participants learned during the first week of training session at UML. We progressively increased the intensity of the home practice sessions by adding the number of sun salutation (SS) over the 12 weeks.
Study NCT01375608 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Decitabine
Description: 0.2mg/kg (range, 0.05-0.3 mg/kg) 1-2X/wk for a period of 48 weeks. Dose and frequency will be determined by hematologic toxicity and the achievement of an HbF level of greater the or equal to 20 percent.
Study NCT03583827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Virtual reality is a simulation of the real world generated by computer software and experienced by users via a man-machine interface, providing them with intensive repetition of complex tasks, directed by visual and auditory stimuli, creating dynamic individual-task interaction, a motivating environment and immediate feedback on performance and results, stimulating motor skill learning and motor control of complex behaviors.
Study NCT03583827 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: Exercises of stretching and strengthening of the upper and lower limbs, as well as coordination, gait and balance.
Study NCT03583827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Description: Exercises of stretching and strengthening of the upper and lower limbs, as well as coordination, gait and balance.
Study NCT00715858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: capsule, 100 mg, b.i.d., 12 months